GE HealthCare Anesthesia Systems Recall
potentially life-threatening risk in Volume Control Ventilation (VCV) modeGE Carestation Anesthesia Systems
GE HealthCare has issued a high-priority correction for certain Carestation anesthesia systems due to a potentially life-threatening risk when used in Volume Control Ventilation (VCV) mode.
Affected Devices
- Carestation 620, 650, 650c
- Carestation 750, 750c
These systems are used in hospitals and surgical settings for delivering anesthesia and ventilatory support to patients of all ages.
The Problem
In VCV mode, the devices affected may fail to ventilate properly. If this happens:
- Alarms and warnings will be triggered (e.g., bellows stop moving, “Unable to Drive Bellows” message, apnea alerts).
- If uncorrected, this can lead to serious injury or death from hypoxia (low oxygen levels).
What to Do
GE HealthCare recommends:
- Do NOT use VCV mode until the device is corrected.
- Use only:
- Pressure Control Ventilation (PCV)
- Pressure Control Ventilation Volume Guarantee (PCV-VG)
- Or manual ventilation
- Perform a Ventilation Screening Test on each system.
- Train your staff and ensure they are aware of the risk and temporary workaround.
- Return the Acknowledgement Form provided in the correction notice.
Questions?
Call GE HealthCare Service at 1-800-437-1171.
If your facility uses these systems, take immediate action to prevent harm. GE HealthCare is currently correcting the devices — no need to remove them from service if alternate modes are used safely.
Urgent Action Required – Baxter LIFE2000 System
Software issue can cause potential harm or death On March 10, the US Food and Drug Administration (FDA) announced that Baxter International Inc. has issued an urgent medical device correction for its LIFE2000 Ventilation System. An issue with the device’ software may...
FDA Approval for Cancer Treatment Aid
The Food and Drug Administration (FDA) on 12 December 2022 announced the approval of Agilent's Resolution CTDX FIRST, a new in vitro diagnostic (IVD) medical device for use in the detecting a specific mutation in the KRAS gene in circulating cell-free DNA. This test...
FDA Posts Warning Letter to MicroVention Costa Rica
Identifies several violations of the FD&C Act and QSR On February 7, FDA issued a warning letter it had sent to MicroVention Costa Rica SRL on September 30, 2022. The company is a subsidiary of MicroVention Inc., a medical device company based in Tustin,...